Transgelin protein may be an indicator of the development of pulmonary arterial hypertension related to congenital heart disease and a potential therapeutic target for the treatment of pulmonary arterial hypertension related to congenital heart disease (Zhou et al., 2022). This evidence concerns the gene TAGLN and congenital heart disease.